Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study

Pierre-Edouard Debureaux; Nathalie Forgeard; Dikelele Elessa; Stéphanie Harel; Laurent Frenzel; Bruno Royer; Alexis Talbot; Sylvain Choquet; Frederic Davi; Florence Nguyen-Khac; Wendy Cuccuini; Morgane Cheminant; Clotilde Bravetti; Gregory Lazarian; Sophie Kaltenbach; Olivier Hermine; Damien Roos-Weil; Marion Espéli; Karl Balabanian; Bertrand Arnulf

doi:10.3324/haematol.2023.283141

Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study

Haematologica. 2024 Jan 1;109(1):325-330. doi: 10.3324/haematol.2023.283141.

Authors

Pierre-Edouard Debureaux¹, Nathalie Forgeard², Dikelele Elessa³, Stéphanie Harel³, Laurent Frenzel⁴, Bruno Royer³, Alexis Talbot³, Sylvain Choquet⁵, Frederic Davi⁶, Florence Nguyen-Khac⁷, Wendy Cuccuini⁸, Morgane Cheminant⁴, Clotilde Bravetti⁶, Gregory Lazarian⁹, Sophie Kaltenbach¹⁰, Olivier Hermine⁴, Damien Roos-Weil⁵, Marion Espéli¹¹, Karl Balabanian¹¹, Bertrand Arnulf¹²

Affiliations

¹ INSERM U1160 EMiLy, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris, France; Department of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris. Pierre-edouard.debureaux@aphp.fr.
² Department of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris, France; Sorbonne Université, Department of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris.
³ Department of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris.
⁴ Department of Hematology, Hospital Necker, Assistance Publique Hopitaux de Paris, Paris.
⁵ Sorbonne Université, Department of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris.
⁶ Laboratory of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris.
⁷ Laboratory of Hematology, Hospital Pitie-Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS1138, Drug Resistance in Hematological Malignancies Team, Paris.
⁸ Laboratory of Cytogenetic, Hospital Saint Louis, Assistance Publique Hopitaux de Paris, Paris.
⁹ Laboratory of Hematology, Hospital Avicenne, Assistance Publique Hopitaux de Paris, Paris.
¹⁰ Laboratory of Hematology, Hospital Necker, Assistance Publique Hopitaux de Paris, Paris.
¹¹ INSERM U1160 EMiLy, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris.
¹² Department of Immuno Hematology, Hospital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris, France; University of Paris Cité, Paris. Bertrand.arnulf@aphp.fr.

No abstract available

MeSH terms

Agammaglobulinaemia Tyrosine Kinase
Humans
Inflammation
Protein Kinase Inhibitors / therapeutic use
Tyrosine Kinase Inhibitors
Waldenstrom Macroglobulinemia* / drug therapy

Substances

Tyrosine Kinase Inhibitors
Agammaglobulinaemia Tyrosine Kinase
Protein Kinase Inhibitors

Grants and funding

Funding: PED received financial support from ITMO Cancer of Aviesan within the framework of the 2021-2030 Cancer Control Strategy on funds administered by INSERM. The "EMiLy" U1160 INSERM unit is a member of the OPALE Carnot Institute, the Organization for Partnerships in Leukemia (Institut Carnot OPALE, Institut de Recherche Saint-Louis, Hôpital Saint-Louis, Paris, France (htpp:www.opale.org;contact@opale.org). KB was a recipient of an FRM grant (EQU202203014627).